1 |
Ader, P., Wessmann, A., and Wolffram, S., Bioavailability and metabolism of the flavonol quercetin in the pig. Free Radical Biol. Med., 28, 1056-1067 (2000)
DOI
ScienceOn
|
2 |
Bardelmeijer, H. A., Beijnen, J. H., Brouwer, K. R., Rosing, H., Nooijen, W. J., Schellens, J. H., and van Tellingen, O., Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin. Cancer Res., 6, 4416-4421 (2000)
|
3 |
Benet, L. Z., Cummins, C. L., and Wu, C. Y., Transporterenzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr. Drug Metab., 4, 393-398 (2003)
DOI
ScienceOn
|
4 |
Cummins, C. L., Jacobsen, W., and Benet, L. Z., Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther., 300, 1036-1045 (2002)
DOI
ScienceOn
|
5 |
Doppenschmitt, S., Spahn-Langguth, H., Regardh, C. G., and Langguth, P., Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein. J. Pharm. Sci., 88, 1067-1072 (1999)
DOI
|
6 |
Eichelbaum, M., Mikus, G., and Vogelgesang, B., Pharmacokinetics of (+)-,(-)- and ()-verapamil after intravenous administration. Brit. J. Clin. Pharmacol., 17, 453-458 (1984)
DOI
ScienceOn
|
7 |
Gould, B. A., Mann, S., Kieso, H., Bala Subramanian, V., and Raftery, E. B., The 24-hour ambulatory blood pressure proflie with verapamil. Circulation, 65, 22-27 (1982)
DOI
ScienceOn
|
8 |
Kroemer, H. K., Gautier, J. C., Beaune, P., Henderson, C., Wolf, C. R., and Eichelbaum, M., Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn- Schmiedeberg's Arch. Pharmacol., 348, 332-337 (1993)
|
9 |
Manach, C., Morand, C., Demigne, C., Texier, O., Regerat, F., and Remesy, C., Bioavailability of rutin and quercetin in rats. FEBS Lett., 409, 12-16 (1997)
DOI
ScienceOn
|
10 |
Rahman, A., Korzekwa, K. R., Grogan, J., Gonzalezs, F. J., Harris, J. W., Selective biotransformation of taxol to 6- hydroxytaxol by human cytochrome P450 2C8. Cancer Res., 54, 5543-5546 (1994)
|
11 |
Schomerus, M., Spiegelhaider, B., Stieren, B., and Eichelbaum, M., Physiologic disposition of verapamil in man. Cardiovasc. Res., 10, 605-612 (1976)
DOI
ScienceOn
|
12 |
Takanaga, H. A., Ohnishi, H., and Matsuo, Y., Sawada, Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells. Biol. Pharm. Bull., 21, 1062-1066 (1998)
DOI
|
13 |
Eagling, V. A., Profit, L., and Back, D. J., Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br. J. Clin. Pharmacol., 48, 543- 552 (1999)
DOI
ScienceOn
|
14 |
Buse, D., Cosme, J. P., Beaune, H. K., and Kroemer, M., Eichelbaum, Cytochromes of the P450 2C subfamily are the major enzymes imvolved in the O-demethylation of verapamil in humans. Naunyn-Schmiedeberg's Arch. Pharmacol., 353, 116-121 (1995)
|
15 |
Dey, C. S., Varma, M. V., Ashokraj, Y., and Panchagnula, R., Pglycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol. Res., 48, 347- 359 (2003)
DOI
ScienceOn
|
16 |
Eichelbaum, M., Remberg, E. G., Schomerus, M., and Dengler, H. J., The metabolism of D,L(14C) verapamil in man. Drug Metab. Dispos., 7, 145-148 (1979)
|
17 |
Dixon, R. A. and Steele, C., Flavonoids and isoflavonoids-gold mine for metabolic engineering. Trends Plant Sci., 4, 394-400 (1999)
DOI
ScienceOn
|
18 |
Meng, X., Maliakal, P., Lu, H., Lee, M. J., and Yang, C. S., Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J. Agric. Food Chem., 52, 935-942 (2004)
DOI
ScienceOn
|
19 |
Krecic-Shepard, M. E., Barmas, C. R., and Schwartz, J. B., Faster clearance of sustained release verapamil in men versus women: Continnuing observations on sex specific differences after oral administration of verapamil. Clin. Pharmacol. Ther., 68, 286-292 (2000)
DOI
ScienceOn
|
20 |
Nijveldt, R. J., van Nood, E., van Hoorn, D. E. C., Boelens, P. G.,van Norren, K., and van Leeuwen, P. A. M., Flavonoids: a review of probable mechanisms of action and potential applications. Am. J. Clin. Nutr., 74, 418-425 (2001)
DOI
|
21 |
Giacomini, J. C., Nelson, W. L., Theodore, L., Wong, F. M., Rood, D., and Giacomini, M., The pharmacokinetics and pharmacodynamics of d- and dl-verapamil in rabbits. J. Cardiovasc Pharmacol., 7, 469-475 (1985)
DOI
|
22 |
Lewis, G. R., Morley, K. D., Lewis, B. M., and Bones, P. J., The treatment of hypertension with verapamil. NZ Medical J., 87, 351-354 (1978)
|
23 |
Takahama, U., Inhibition of lipoxygenase-dependent lipid peroxidation by quercetin: mechanism of antioxidative function. Phytochemistry, 24, 1443 -1446 (1985)
DOI
ScienceOn
|
24 |
Kumar, G. N., Walle, U. K., and Walle, T., Cytochome P450 3Amediated human liver microsomal taxol 6-hydroxylation. J. Pharmacol. Exp. Ther., 268, 1160-1165 (1994)
|
25 |
Zhang, H., Wong, C. W., Coville, P. G., and Wanwimolruk, S., Effect of the grapefruit flavonoid naringin on pharmacokinetics of quinine in rats. Drug Metabol. Drug Interact., 17, 351-363 (2000)
|
26 |
Mori, Y., Hanada, K., Mori, T., Tsukahara, Y., Hashiguchi, M., and Ogata, H., Stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil in rabbits. Biol. Pharm. Bull., 24, 806-810 (2001)
DOI
ScienceOn
|
27 |
Cody, V., Plant Flavonoids in Biology and Medicine, part II. Prog. Clin. Biol. Res., 280, 111-120 (1988)
|
28 |
Rocci, M. L. and Jusko, W. J., LAGRAN program for area and moments in pharmacokinetic analysis. Comp. Prog. In. Biomed., 16, 203-209 (1983)
DOI
ScienceOn
|
29 |
Cody, V., Plant Flavoniods in Biology and Medicine. Prog. Clin. Biol. Res., 213, 233-239 (1986)
|
30 |
Dupuy, J., Larrieu, G., Sutra, J. F., Lespine, A., and Alvinerie, M., Enhancement of moxidectin bioavailability in lamb by a natural flavonoid. Vet. Parasitol., 112, 337-347 (2003)
DOI
ScienceOn
|
31 |
Hodek, P., Trefil, P., and Stiborova, M., Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem. Biol. Interact., 139, 1-21 (2002)
DOI
ScienceOn
|
32 |
Fleckenstein, A., Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Ann. Rev. Pharmacol. Toxicol., 17, 149-166 (1977)
DOI
ScienceOn
|
33 |
Kim, H. J. and Choi, J. S., Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, narverapamil, in rabbits. Biopharm. Drug Dispos., 26, 295- 300 (2005)
DOI
ScienceOn
|
34 |
Wacher, V. J., Salphati, L., and Benet, L. Z., Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Deliver. Rev., 20, 99-112 (1996)
DOI
ScienceOn
|
35 |
Davis, J., Williams, L. S., Hill, D., and Lowenthal, D. T., Effects of fosinopril or sustained-release verapamil on blood pressure and serum techolamine concentrations in elderly hypertensive men. Am. J. Ther., 7, 3-9 (2000)
DOI
|
36 |
Doostdar, H., Burke, M. D., and Mayer, R. T., Bioflavoniods: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology, 144, 31-38 (2000)
DOI
ScienceOn
|
37 |
Kim, D. H., Jung, E. A., Shong, I. S., and Han, J. A., Intestinal bacterial metabolism of flavonoids and its relation to some biological activities. Arch. Pharm. Res., 21, 17-23 (1998)
DOI
|
38 |
Ho, P. C., Saville, D. J., and Wanwimolruk, S., Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J. Pharm. Pharm. Sci., 4, 217-227 (2001)
|